Revenue Insights: Bio-Techne Corporation and Amneal Pharmaceuticals, Inc. Performance Compared

Revenue Growth in the Biotech and Pharmaceutical Sectors

In the past decade, Bio-Techne Corporation and Amneal Pharmaceuticals, Inc. have demonstrated significant revenue growth, reflecting broader trends in the biotech and pharmaceutical industries. From 2014 to 2023, Amneal Pharmaceuticals saw its revenue soar by over 200%, peaking at approximately $2.39 billion in 2023. This growth underscores the company's strategic expansions and product innovations.

Meanwhile, Bio-Techne Corporation experienced a steady increase in revenue, nearly tripling from 2014 to 2023, reaching around $1.14 billion. This growth trajectory highlights Bio-Techne's successful adaptation to market demands and its robust product pipeline.

The data reveals a consistent upward trend for both companies, with Amneal Pharmaceuticals leading in revenue figures. However, the absence of data for Amneal in 2024 suggests potential challenges or reporting delays. These insights provide a compelling snapshot of the dynamic and competitive landscape of the biotech and pharmaceutical sectors.